Unternehmen Foamix Pharmaceuticals Ltd. Nasdaq
Aktien
A12BKW
IL0011334385
Biotechnologie
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 01.03.20 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 01.03.20 |
Mutya Harsch
LAW | General Counsel | 50 | 01.03.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 10.09.20 |
Steven Basta
BRD | Director/Board Member | 59 | 01.01.15 |
Anthony Bruno
BRD | Director/Board Member | 68 | 01.03.20 |
Director/Board Member | 62 | 01.03.19 | |
David Domzalski
CEO | Chief Executive Officer | 58 | 01.03.20 |
Director/Board Member | - | 01.01. | |
Sharon Barbari
BRD | Director/Board Member | 70 | 01.03.20 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 14 528 247 | 13 300 238 ( 91,55 %) | 0 | 91,55 % |
Unternehmenskontakt
VYNE Therapeutics, Inc.
685 Route 202/206 North Suite 301
08807, Bridgewater
+
http://www.vynetherapeutics.com![Straße Foamix Pharmaceuticals Ltd.](https://cdn.zonebourse.com/static/address/17927322.png)
Sektor
% 1. Jan. | Kap. | |
---|---|---|
+20.17% | 127 Mrd. | |
+24.67% | 117 Mrd. | |
+25.44% | 27.67 Mrd. | |
-17.74% | 20.33 Mrd. | |
-15.17% | 16.79 Mrd. | |
-15.21% | 15.63 Mrd. | |
+11.91% | 14.84 Mrd. | |
-47.10% | 14.65 Mrd. | |
+54.50% | 14.43 Mrd. |